05:57 PM EDT, 03/17/2026 (MT Newswires) -- Beyond Air ( XAIR ) unit Beyond Cancer said its Phase 1 clinical trial evaluating a single intratumoral injection of ultra-high-concentration nitric oxide administered as monotherapy for cutaneous or subcutaneous primary or metastatic lesions showed a favorable safety and tolerability profile.

Seven of the 10 patients in the study remained alive between 19 and 37 months after a single dose as of Oct. 1, 2025, the company said Tuesday in a statement.

Most treatment-related adverse events were grade 1, with one serious adverse event of hypoxia that fully resolved, the company said.